Table 3.

Mean glucose levels and time in target for inpatient CL admissions

	CL alone	CL + adjunctive therapy	P value
Pramlintide
Daytime (8:00 a.m.–11:00 p.m.)
Mean blood glucose (mg/dL)	166 ± 47	160 ± 40	0.08
<70 mg/dL	1.9	0.3
70–180 mg/dL	59.7	71.1	0.004
>180 mg/dL	38.4	28.5
Nocturnal (11:00 p.m.–6:00 a.m.)
Mean blood glucose (mg/dL)	121 ± 20	122 ± 28	0.87
<70 mg/dL	0	2.7
70–180 mg/dL	98.7	93.3	0.12
>180 mg/dL	1.3	4
Liraglutide
Daytime (8:00 a.m.–11:00 p.m.)
Mean blood glucose (mg/dL)	143 ± 55	146 ± 47	0.13
<70 mg/dL	5.9	3.3
70–180 mg/dL	71.6	74.4	0.50
>180 mg/dL	22.4	22.3
Nocturnal (11:00 p.m.–6:00 a.m.)
Mean blood glucose (mg/dL)	104 ± 23	113 ± 24	0.0001
<70 mg/dL	5.5	2.4
70–180 mg/dL	94.5	96.4	0.13
>180 mg/dL	0	1.2

Data are mean ± SD for glucose levels and percent of time in various ranges (<70, 70–180, and >180 mg/dL). System target glucose was 120 mg/dL for the pramlintide study and 100 mg/dL for the liraglutide study.